Connecticut Drug Laws: Penalties, Charges & Treatment Options

Connecticut regulates controlled substances through Chapter 420b of the Connecticut General Statutes (C.G.S. § 21a-240 et seq.), known as the Dependency-Producing Drugs law. The state classifies controlled substances into five schedules (I–V) under C.G.S. § 21a-243, mirroring the federal Controlled Substances Act framework. Connecticut distinguishes between simple possession, which was reduced from a felony to a Class A misdemeanor in 2015, and sale or manufacturing offenses, which remain serious felonies.

Connecticut legalized adult-use recreational marijuana through Senate Bill 1201, signed into law on June 22, 2021. Adults 21 and older may possess up to 1.5 ounces on their person and up to 5 ounces in a locked container at home. Home cultivation of up to 6 plants per person (3 mature, 12 per household) became legal on July 1, 2023. Licensed retail sales of recreational cannabis began in January 2023.

The state provides several pathways for treatment-based alternatives to incarceration, including pretrial drug education and community service programs under C.G.S. § 54-56i, suspended prosecution for drug-dependent persons, and various diversion initiatives. Connecticut also has strong overdose prevention measures, including a Good Samaritan immunity law and expansive naloxone access provisions.

Connecticut Controlled Substance Possession Penalties

Under C.G.S. § 21a-279, Connecticut law distinguishes between possession of narcotic substances and other controlled substances:

Narcotic Substances (C.G.S. § 21a-279(a))

Possession of any quantity of a narcotic substance (including heroin, cocaine, crack cocaine, fentanyl, methadone, morphine, and oxycodone) is punishable as follows:

• First offense: Up to 7 years imprisonment and/or a fine of up to $50,000 (Class D Felony)
• Subsequent offense: Enhanced penalties may apply; court may order substance abuse evaluation

Non-Narcotic Controlled Substances (C.G.S. § 21a-279(c))

Possession of any other controlled substance (Schedules I–V, non-narcotic) is a Class A Misdemeanor:

• Up to 1 year imprisonment and/or fine of up to $2,000
• Second offense: court shall evaluate for drug dependency and may suspend prosecution for treatment
• Third or subsequent offense: may be charged as persistent offender — Class E Felony (up to 3 years, $3,500 fine)

Cannabis Possession (Adults 21+)

Under C.G.S. § 21a-279a and SB 1201 (2021):

• Up to 1.5 oz on person: Legal
• Up to 5 oz at home in locked container: Legal
• Over 1.5 oz on person (or improperly stored over 1.5 oz): Infraction, $150 fine

Good Samaritan Immunity (C.G.S. § 21a-279(d))

A person who in good faith seeks medical assistance for someone experiencing a drug overdose shall not be arrested or prosecuted for possession of a controlled substance if the evidence was obtained as a result of seeking such assistance.

Connecticut Operating Under the Influence (OUI) Laws

Connecticut uses the term Operating Under the Influence (OUI) rather than DUI or DWI. Under C.G.S. § 14-227a, it is illegal to operate a motor vehicle while under the influence of intoxicating liquor or any drug or both, or while having an elevated blood alcohol content.

BAC Limits

• Standard (21+): 0.08%
• Commercial drivers: 0.04%
• Under 21: 0.02%

Criminal Penalties

Drug-Impaired Driving

Connecticut's OUI statute applies equally to alcohol and drug impairment, including prescription medications. There is no per se drug concentration limit; impairment is assessed through Drug Recognition Expert (DRE) evaluations, field sobriety testing, and blood/urine toxicology.

Implied Consent

Under C.G.S. § 14-227b, Connecticut is an implied consent state. Refusal to submit to chemical testing results in an automatic 45-day license suspension for a first refusal and longer suspensions for subsequent refusals.

Connecticut has extensive naloxone access provisions. Under C.G.S. § 21a-286, pharmacists may prescribe and dispense naloxone to individuals pursuant to a standing order from a prescribing practitioner. Since the FDA approved over-the-counter Narcan nasal spray in March 2023, naloxone is also available without a prescription at pharmacies statewide. Connecticut exempted nonprescription opioid antagonists from state sales and use tax in 2023, and created the Opioid Antagonist Bulk Purchase Fund (effective January 1, 2024) through DMHAS to distribute naloxone to municipalities, EMS organizations, and eligible entities at no cost.

• Pharmacists may dispense naloxone under standing orders from prescribing practitioners (C.G.S. § 21a-286).
• Over-the-counter naloxone (Narcan nasal spray) available at pharmacies without prescription.
• Nonprescription opioid antagonists are exempt from Connecticut sales and use tax (PA 23-204).
• Opioid Antagonist Bulk Purchase Fund (PA 23-171) provides free naloxone to municipalities and EMS since January 2024.
• PA 23-97 requires practitioners to encourage patients to obtain an opioid antagonist when prescribing opioids.
• PA 24-19 requires dispensation of drug deactivation pouches with opioid prescriptions.
• Civil and criminal liability protections for healthcare professionals and laypersons who administer naloxone in good faith.
• Fentanyl test strips are explicitly excluded from drug paraphernalia laws.

Connecticut Department of Mental Health and Addiction Services (DMHAS) and Department of Consumer Protection (DCP)

https://portal.ct.gov/dmhas

Connecticut notably closed its remaining drug courts by the end of 2024, becoming the only U.S. state or territory without an active specialty drug court. However, Connecticut continues to operate several alternative treatment and diversion programs for individuals with substance use disorders who are involved in the criminal justice system.

• Pretrial Drug Education and Community Service Program (C.G.S. § 54-56i)
  Description: Eligible defendants charged with simple drug possession may participate in a drug education program and perform community service in lieu of prosecution.
• Suspended Prosecution for Drug-Dependent Persons (C.G.S. § 21a-279(b))
  Description: Courts may suspend prosecution for second-offense possession defendants found to be drug-dependent and order substance abuse treatment.
• Addiction Intervention Program (ADI) (N/A (successor to New Haven Drug Court))
  Description: Intensive outpatient substance abuse treatment program serving 100-120 New Haven residents annually, providing case management, employment support, and linkage to recovery services.
• ASIST (Alternative to Incarceration Services)
  Description: Court-based diversionary program for persons with psychiatric and co-occurring substance use disorders, offering judicial supervision integrated with mental health and addiction recovery services.
• Jail Diversion / Court Liaison Programs
  Description: Court-based services providing assessment, referral, and linkage to community mental health and substance abuse treatment for persons arrested on minor offenses.

Connecticut Judicial Branch; Department of Mental Health and Addiction Services (DMHAS)

Connecticut imposes mandatory minimum sentences for certain serious drug offenses, primarily targeting large-scale distribution and drug-free zone violations. Simple possession does not carry mandatory minimums. The Connecticut Sentencing Commission has advocated for reforms to mandatory minimum drug sentences.

• Sale of narcotics by non-drug-dependent person (large quantities) — Statute: C.G.S. § 21a-278(a)
  Minimum: 5 years (1st offense); 10 years (subsequent)
  Details: Applies to 1 oz+ heroin/methadone, 0.5 oz+ cocaine, or 5mg+ LSD. Mandatory minimum is non-suspendable except for persons under 18 or with significantly impaired mental capacity.
• Sale within drug-free zone (school, day care, public housing) — Statute: C.G.S. § 21a-278a(b)
  Minimum: 3 years consecutive
  Details: Mandatory 3-year sentence, non-suspendable, in addition to and consecutive with any underlying sentence. Applies within 1,500 feet of schools, licensed child day care centers, or public housing projects.
• Sale of drugs to a minor — Statute: C.G.S. § 21a-278a(a)
  Minimum: 2 years consecutive
  Details: Mandatory 2-year sentence, non-suspendable, consecutive to underlying offense.
• Using a minor to sell drugs — Statute: C.G.S. § 21a-278a(c)
  Minimum: 3 years consecutive
  Details: Mandatory 3-year sentence, non-suspendable, consecutive to underlying offense.

Judges may impose less than the mandatory minimum when: (1) no one was physically harmed during the crime, (2) the defendant did not use, attempt, or threaten physical force, (3) the defendant was unarmed, and (4) the defendant did not use or threaten use of a deadly weapon. The defendant must show good cause and may invoke this provision only once.

Connecticut offers multiple pathways for substance abuse treatment as an alternative to incarceration, reflecting the state's emphasis on rehabilitation over punishment for drug offenses, particularly simple possession.

• Pretrial Drug Education and Community Service (Accelerated Rehabilitation) (C.G.S. § 54-56i; C.G.S. § 54-56e (AR))
  Description: First-time offenders charged with drug possession may apply for accelerated rehabilitation, which includes drug education classes, community service, and a probationary period. Successful completion results in dismissal of charges.
  Eligibility: Generally available to first-time offenders with no prior felony convictions.
• Suspended Prosecution for Drug Dependency (C.G.S. § 21a-279(b))
  Description: On a second possession offense, the court shall evaluate the defendant and, if found to be drug-dependent, may suspend prosecution and order substance abuse treatment.
  Eligibility: Second-time drug possession offenders evaluated as drug-dependent.
• DMHAS Community-Based Treatment
  Description: The Department of Mental Health and Addiction Services operates a statewide network of treatment programs including detoxification, residential treatment, outpatient counseling, and medication-assisted treatment (MAT) with methadone, buprenorphine, and naltrexone.
  Eligibility: Open to Connecticut residents; many programs accept referrals from the criminal justice system.
• Community Forensic Services
  Description: DMHAS Community Forensic Services provides court-based treatment recommendations, diversion services, and community supervision for persons with substance use and mental health disorders in the criminal justice system.
  Eligibility: Persons with substance use and/or mental health disorders involved in the criminal justice system.

2024: Prohibited the manufacture and sale of synthetic cannabinoids and empowered DCP to regulate cannabis dosage, potency, and packaging. Required the DCP Commissioner to designate synthetic cannabinoids as Schedule I controlled substances.

2024: Required the dispensation of drug deactivation pouches with opioid prescriptions to facilitate safe disposal of unused medications.

2023: Beginning July 1, 2023, Connecticut residents 21+ may cultivate up to 6 cannabis plants per person (3 mature maximum), with a household cap of 12 plants.

2023: Created a non-lapsing fund for DMHAS to purchase and distribute opioid antagonists (naloxone) to municipalities, EMS organizations, and eligible entities starting January 1, 2024.

2023: Added nonprescription opioid antagonists to the list of drugs exempt from Connecticut sales and use tax.

2023: Required practitioners to encourage patients to obtain an opioid antagonist when prescribing opioids. For minors, the encouragement must also extend to the parent or guardian if present. Opioid prescriptions for first-time outpatient use are limited to a 7-day supply.

2023: Licensed retail sales of recreational cannabis began in January 2023 through approved dispensaries, following the framework established by SB 1201 (2021).

2023: Municipalities receiving opioid settlement funds must report annually to the Opioid Settlement Advisory Committee on their expenditures until all funds are spent.